𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Regulation of myeloid cell function and major histocompatibility complex class II expression by tumor necrosis factor

✍ Scribed by Ruediger B. Mueller; Alla Skapenko; Mathias Grunke; Jörg Wendler; Bruno Stuhlmuller; Joachim R. Kalden; Hendrik Schulze-Koops

Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
145 KB
Volume
52
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Regulation of peptide presentation by ma
Regulation of peptide presentation by major histocompatibility complex class II molecules at the surface of macrophages
✍ Alexei von Delwig; Julie A. Musson; Norman McKie; Joe Gray; John H. Robinson 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 283 KB

We studied major histocompatibility complex class II-dependent presentation of two T cell epitopes delivered as synthetic peptides by fixed macrophages. Treatment of bone marrow macrophages with inhibitors of proteinases of the metallo-, aspartic and serine proteinase families enhanced presentation

The overlooked “nonclassical” functions
The overlooked “nonclassical” functions of major histocompatibility complex (MHC) class II antigens in immune and nonimmune cells
✍ Maresa Altomonte; Carlo Pucillo; Michele Maio 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 159 KB 👁 2 views

Besides their "classical" antigenic peptide-presenting activity, major histocompatibility complex (MHC) class II antigens can activate different cellular functions in immune and nonimmune cells. However, this "nonclassical" role and its functional consequences are still substantially overlooked. In

The effect of photodynamic therapy on tu
The effect of photodynamic therapy on tumor cell expression of major histocompatibility complex (MHC) class I and MHC class I-related molecules
✍ Alan Belicha-Villanueva; Jonah Riddell; Naveen Bangia; Sandra O. Gollnick 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 299 KB

## Abstract ## Background and Objective Photodynamic therapy (PDT) is FDA‐approved anti‐cancer modality for elimination of early disease and palliation in advanced disease. PDT efficacy depends in part on elicitation of a tumor‐specific immune response that is dependent on cytotoxic T lymphocytes